Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Official title: A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04-02
Completion Date
2030-06-30
Last Updated
2026-04-30
Healthy Volunteers
No
Conditions
Interventions
ADX-324 Dose Level 1
siRNA duplex oligonucleotide
ADX-324 Dose Level 2
siRNA duplex oligonucleotide
Locations (48)
ADARx Clinical Site
Litchfield Park, Arizona, United States
ADARx Clinical Site
Little Rock, Arkansas, United States
ADARx Clinical Site
San Diego, California, United States
ADARx Clinical Site
Walnut Creek, California, United States
ADARx Clinical Site
Orlando, Florida, United States
ADARx Clinical Site
Chevy Chase, Maryland, United States
ADARx Clinical Site
Wheaton, Maryland, United States
ADARx Clinical Site
Detroit, Michigan, United States
ADARx Clinical Site
St Louis, Missouri, United States
ADARx Clinical Site
Las Vegas, Nevada, United States
ADARx Clinical Site
New York, New York, United States
ADARx Clinical Site
Cincinnati, Ohio, United States
ADARx Clinical Site
Columbus, Ohio, United States
ADARx Clinical Site
Toledo, Ohio, United States
ADARx Clinical Site
Hershey, Pennsylvania, United States
ADARx Clinical Site
Capital Federal, Buenos Aires, Argentina
ADARx Clinical Site
Buenos Aires, Buenos Aires F.D., Argentina
ADARx Clinical Site
Adelaide, South Australia, Australia
ADARx Clinical Site
Vienna, Austria
ADARx Clinical Site
Edegem, Antwerpen, Belgium
ADARx Clinical Site
Sofia, Bulgaria
ADARx Clinical Site
Edmonton, Alberta, Canada
ADARx Clinical Site
Ottawa, Ontario, Canada
ADARx Clinical Site
Montreal, Quebec, Canada
ADARx Clinical Site
Beijing, China
ADARx Clinical Site
Harbin, China
ADARx Clinical Site
Zhengzhou, China
ADARx Clinical Site
Split, Croatia
ADARx Clinical Site
Zagreb, Croatia
ADARx Clinical Site
Hradec Králové, Czechia
ADARx Clinical Site
Prague, Czechia
ADARx Clinical Site
Nice, Alpes-Maritimes, France
ADARx Clinical Site
Tours, Indre-et-Loire, France
ADARx Clinical Site
Montpellier, France
ADARx Clinical Site
Paris, France
ADARx Clinical Site
Tübingen, Baden-Wurttemberg, Germany
ADARx Clinical Site
Hong Kong, Hong Kong
ADARx Clinical Site
Budapest, Hungary
ADARx Clinical Site
Ashkelon, Israel
ADARx Clinical Site
Tel Aviv, Israel
ADARx Clinical Site
Lodz, Poland
ADARx Clinical Site
Barcelona, Spain
ADARx Clinical Site
Madrid, Spain
ADARx Clinical Site
Taichung, Taiwan
ADARx Clinical Site
Cambridge, United Kingdom
ADARx Clinical Site
Cardiff, United Kingdom
ADARx Clinical Site
London, United Kingdom
ADARx Clinical Site
Southampton, United Kingdom